FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Sofie Co dba Sofie Florbetaben F-18 Recall

Florbetaben F-18 (Neuraceq¿) Injection Solution 1

Sofie Co dba Sofie · Sterling, VA

Risk level
Class II
Reported by FDA
Oct 4, 2023
Recall ID
D-1177-2023
Check your lot numberHow we source this data

Summary

Sofie Co dba Sofie recalled Florbetaben F-18 starting Aug 22, 2023. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1177-2023 on Oct 4, 2023. Reason: Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT). Status: Terminated.

Why it was recalled

Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT).

Product description

Florbetaben F-18 (Neuraceq¿) Injection Solution 1.4 to 135 mCi/mL, 50 mL in 1 multi-dose glass vial, Diagnostic-For Intravenous Use Only, Manufactured by SOFIE Co dba SOFIE, Dulles, VA 20166 for Life Molecular Imagining Ltd., NDC 54828-001-50

Lot numbers, UPCs & expiration codes

Batch # FBBVA123082201, EOS: 22 Aug 2023/08:25, EXP: 22 Aug 2023/18:25

Where it was sold

Product was released to one facility in VA.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1177-2023
Classification
Class II
Status
Terminated
Recall initiated
Aug 22, 2023
FDA report date
Oct 4, 2023
Quantity
6 patient doses
Recall type
Voluntary: Firm initiated
Recalling firm
Sofie Co dba Sofie

Original FDA data

Every field from FDA enforcement report D-1177-2023, exactly as published.

Show all FDA fields
City
Sterling
State
VA
Status
Terminated
Country
United States
Event ID
93073
Address
100 Executive Dr Ste 6
Code information
Batch # FBBVA123082201, EOS: 22 Aug 2023/08:25, EXP: 22 Aug 2023/18:25
Postal code
20166-9507
Report date
Oct 4, 2023
Product type
Drugs
Recall number
D-1177-2023
Classification
Class II
Recalling firm
Sofie Co dba Sofie
Product quantity
6 patient doses
Termination date
Dec 4, 2023
Reason for recall
Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT).
Voluntary / mandated
Voluntary: Firm initiated
Product description
Florbetaben F-18 (Neuraceq¿) Injection Solution 1.4 to 135 mCi/mL, 50 mL in 1 multi-dose glass vial, Diagnostic-For Intravenous Use Only, Manufactured by SOFIE Co dba SOFIE, Dulles, VA 20166 for Life Molecular Imagining Ltd., NDC 54828-001-50
Distribution pattern
Product was released to one facility in VA.
Recall initiation date
Aug 22, 2023
Initial firm notification
Telephone
Center classification date
Sep 26, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1177-2023, published Oct 4, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls